All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @strongarm2020 on TikTok · 37s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @strongarm2020's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Thanks for watching!
  2. 0:30.

@strongarm2020's peptide weight loss claims, fact-checked

Joshua

TikTok creator

75.8K viewsWatch on TikTok

Quick answer

Retatrutide is an experimental triple-hormone receptor agonist (GLP-1, GIP, glucagon) currently in Phase 3 trials by Eli Lilly. The Phase 2 TRIUMPH-1 study showed 24.2% weight loss at 48 weeks, but long-term safety data beyond one year doesn't exist yet.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @strongarm2020's peptide weight loss claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

@strongarm2020's peptide weight loss claims, fact-checked should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@strongarm2020's peptide weight loss claims, fact-checked" from Joshua. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Retatrutide is an experimental triple-hormone receptor agonist (GLP-1, GIP, glucagon) currently in Phase 3 trials by Eli Lilly.

The reason this review is not generic is the source wording and the canonical claim label "peptides down 30lbs and in the best shape i have ever been disclaime." In this clip, the useful excerpt is: "Thanks for watching!" That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

The drug won't complete FDA approval until around 2026 after Phase 3 trials finish
People who land here are usually comparing the Peptide social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Peptide social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Retatrutide is an experimental triple-hormone receptor agonist (GLP-1, GIP, glucagon) currently in Phase 3 trials by Eli Lilly.

FormBlends verdict

Peptide social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Retatrutide is an experimental triple-hormone receptor agonist (GLP-1, GIP, glucagon) currently in Phase 3 trials by Eli Lilly. The Phase 2 TRIUMPH-1 study showed 24.2% weight loss at 48 weeks, but long-term safety data beyond one year doesn't exist yet.
  • Retatrutide showed 24.2% weight loss in the Phase 2 TRIUMPH-1 trial, but it's still experimental
  • The drug won't complete FDA approval until around 2026 after Phase 3 trials finish

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Retatrutide showed 24.2% weight loss in the Phase 2 TRIUMPH-1 trial, but it's still experimental
  • The drug won't complete FDA approval until around 2026 after Phase 3 trials finish
  • Serious side effects occurred in 4.2% of trial participants at the highest dose
  • Over 70% of users experienced nausea, vomiting, or diarrhea in clinical trials
  • Research chemicals sold online lack FDA quality control and purity standards
  • FDA-approved alternatives like semaglutide achieve 15-20% weight loss with established safety profiles
  • Long-term safety data beyond 48 weeks doesn't exist for retatrutide yet

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What does this TikTok actually claim?

Joshua (@strongarm2020) claims he's lost 30 pounds using peptides and is in the best shape of his life. He includes a disclaimer that peptides aren't FDA approved for human use.

The #reta hashtag suggests he's likely using retatrutide, an experimental triple-hormone receptor agonist currently in clinical trials. He doesn't specify dosage, timeline, or other details about his protocol.

Credit where it's due: Joshua includes the required disclaimer about FDA approval status. That's more responsible than most peptide influencers on social media.

Is retatrutide actually effective for weight loss?

Early clinical data shows retatrutide is remarkably effective, potentially outperforming existing GLP-1 drugs. The Phase 2 TRIUMPH-1 trial found 24.2% weight loss at 48 weeks with the highest dose.

But here's the catch: this was a 338-person study, not the thousands needed for full approval. Participants also received intensive lifestyle counseling every four weeks.

Retatrutide targets GLP-1, GIP, and glucagon receptors simultaneously. This triple action appears more potent than semaglutide or tirzepatide, which only hit one or two targets respectively.

What are the risks Joshua isn't mentioning?

The TRIUMPH-1 trial reported serious side effects in 4.2% of participants at the highest dose. Most common issues were gastrointestinal: nausea, vomiting, and diarrhea affected over 70% of users.

More concerning: we have zero long-term safety data beyond 48 weeks. Joshua's treating his body like a clinical trial with unknown endpoints.

The research-grade peptides available online aren't regulated for purity or dosing accuracy. You're essentially buying chemicals from labs with no quality control or medical oversight.

Why isn't retatrutide FDA approved yet?

Eli Lilly is still running Phase 3 trials, expected to complete in 2026. The FDA requires extensive safety data across thousands of participants before approval.

Current trials are testing long-term cardiovascular outcomes, not just weight loss. Previous weight loss drugs have been pulled from market due to heart valve problems and other serious complications discovered later.

The "research chemical" versions circulating online are made by compounding labs or overseas manufacturers with no FDA oversight. That's a massive quality control gamble.

What should you actually know about peptide weight loss?

If you want proven GLP-1 therapy, stick with FDA-approved options like semaglutide or tirzepatide. Both have extensive safety data and legitimate prescribing pathways through licensed providers.

Joshua's 30-pound loss could easily be achieved with approved medications under proper medical supervision. The STEP trials showed 15-20% body weight reduction with semaglutide.

Don't let social media influencers become your clinical trial designers. The research looks promising, but retatrutide needs to complete the approval process before anyone can recommend it safely.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Joshua · TikTok creator

75.8K views on this video

Down 30lbs and in the best shape I have ever been. Disclaimer *Peptides are not FDA approved and not for human use. #peptide #reta #weightloss #peptideresults

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about retatrutide showed 24.2% weight loss in the phase 2 triumph-1?

Retatrutide showed 24.2% weight loss in the Phase 2 TRIUMPH-1 trial, but it's still experimental

What does the video say about the drug won't complete fda approval until around 2026 after?

The drug won't complete FDA approval until around 2026 after Phase 3 trials finish

What does the video say about serious side effects occurred in 4.2% of trial participants at?

Serious side effects occurred in 4.2% of trial participants at the highest dose

What does the video say about over 70% of users experienced nausea, vomiting,?

Over 70% of users experienced nausea, vomiting, or diarrhea in clinical trials

What does the video say about research chemicals sold online lack fda quality control?

Research chemicals sold online lack FDA quality control and purity standards

What does the video say about fda-approved alternatives like semaglutide achieve 15-20% weight loss with established?

FDA-approved alternatives like semaglutide achieve 15-20% weight loss with established safety profiles

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Joshua, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.